| Filed On | Filing |
|---|---|
| 29 Sep 2026 |
8-K: Regulation FD Disclosure
LEXINGTON, Mass., September 29, 2026, (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of... |
| 28 Sep 2026 |
8-K: Regulation FD Disclosure
LEXINGTON, Mass., September 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of ... |
| 08 Sep 2026 |
8-K: Other Events
LEXINGTON, Mass., September 8, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat ... |
| 03 Aug 2026 | 8-K: Regulation FD Disclosure |
| 03 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 30 Jul 2026 | 8-K: Regulation FD Disclosure |
| 22 Jul 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 25 Jun 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure |
| 03 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 01 Jun 2026 | 8-K: Regulation FD Disclosure |
| 14 May 2026 | 8-K: Results of Operations and Financial Condition |
| 09 Mar 2026 | 8-K: Other Events |
| 04 Mar 2026 | 8-K: Regulation FD Disclosure |
| 04 Mar 2026 | 8-K: Results of Operations and Financial Condition |
| 26 Feb 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure |
| 18 Feb 2026 | 8-K: Regulation FD Disclosure |
| 09 Jan 2026 | 8-K: Regulation FD Disclosure |
| 05 Nov 2025 | 8-K: Results of Operations and Financial Condition |
| 15 Oct 2025 | 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +3 more |
| 08 Sep 2025 | 8-K: Other Events |
Loading...
